Skip to main content
. 1999 Mar 2;96(5):2268–2273. doi: 10.1073/pnas.96.5.2268

Figure 2.

Figure 2

Systemic administration of IL-2 can enhance the capacity of MCA-207 tumor lysate-pulsed DC to induce tumor-specific CTL (Top and Middle) and IFN-γ production (Bottom) in vivo. Mice were immunized twice weekly following the schedule described in Fig. 1. Spleens were harvested 7 days after the final IL-2 (or HBSS) injection from mice treated with either HBSS, MCA-207 tumor lysate-pulsed DC plus IL-2, MCA-207 tumor lysate-pulsed DC alone, or IL-2 alone. Details of the generation and testing of these CTL are provided in Materials and Methods. Values are the mean ± SEM of triplicate wells at a 100:1 effector-to-target ratio. For measurement of IFN-γ production (Bottom), splenic T cells from the treated mice were stimulated in vitro as described. Culture supernatants were harvested 48 hr later and evaluated for IFN-γ levels by ELISA (in units/ml; mean ± SEM of triplicate samples).